Monoclonal antibodies against Claudin-18 for treatment of cancer
AssigneesAstellas Pharma Inc., Tron—Translationale Onkologie An Der Universitat
InventorsUgur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Claims18
An antibody that binds to CLD18A2 and mediates killing of cells expressing CLD18A2, wherein said antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), each of the VH and VL comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3:
- VH:
- CDR1:
- positions 45-52 of SEQ ID NO:
- 118, CDR2:
- positions 70-77 of SEQ ID NO:
- 118, CDR3:
- positions 116-126 of SEQ ID NO:
- 118, VL:
- CDR1:
- positions 47-58 of SEQ ID NO:
- 125, CDR2:
- positions 76-78 of SEQ ID NO:
- 125, CDR3:
- positions 115-123 of SEQ ID NO:
- 125,
- wherein the VH and VL domains of the antibody are expressed on a single polypeptide chain.
Dependencies are inferred from the claim text.